The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Retinal Dystrophy Treatment Market Research Report 2025
Synopsis
The global Retinal Dystrophy Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Retinal Dystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Dystrophy Treatment.
Report Scope
The Retinal Dystrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Retinal Dystrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Retinal Dystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Spark Therapeutics (Roche)
Novartis AG
GlaxoSmithKline
Applied Genetic Technologies Corporation
Oxford BioMedica
Biogen
HORAMA S.A.
MeiraGTx Limited
Novelion Therapeutics
IVERIC bio
Reflection Biotechnologies
Segment by Type
Gene Therapy Treatment
Symptomatic Treatment
Segment by Application
Hospitals
Specialty Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Retinal Dystrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Retinal Dystrophy Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Retinal Dystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Retinal Dystrophy Treatment.
Report Scope
The Retinal Dystrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Retinal Dystrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Retinal Dystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Spark Therapeutics (Roche)
Novartis AG
GlaxoSmithKline
Applied Genetic Technologies Corporation
Oxford BioMedica
Biogen
HORAMA S.A.
MeiraGTx Limited
Novelion Therapeutics
IVERIC bio
Reflection Biotechnologies
Segment by Type
Gene Therapy Treatment
Symptomatic Treatment
Segment by Application
Hospitals
Specialty Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Retinal Dystrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Retinal Dystrophy Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gene Therapy Treatment
1.2.3 Symptomatic Treatment
1.3 Market by Application
1.3.1 Global Retinal Dystrophy Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Retinal Dystrophy Treatment Market Perspective (2019-2030)
2.2 Retinal Dystrophy Treatment Growth Trends by Region
2.2.1 Global Retinal Dystrophy Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Retinal Dystrophy Treatment Historic Market Size by Region (2019-2024)
2.2.3 Retinal Dystrophy Treatment Forecasted Market Size by Region (2025-2030)
2.3 Retinal Dystrophy Treatment Market Dynamics
2.3.1 Retinal Dystrophy Treatment Industry Trends
2.3.2 Retinal Dystrophy Treatment Market Drivers
2.3.3 Retinal Dystrophy Treatment Market Challenges
2.3.4 Retinal Dystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Retinal Dystrophy Treatment Players by Revenue
3.1.1 Global Top Retinal Dystrophy Treatment Players by Revenue (2019-2024)
3.1.2 Global Retinal Dystrophy Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Retinal Dystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Retinal Dystrophy Treatment Revenue
3.4 Global Retinal Dystrophy Treatment Market Concentration Ratio
3.4.1 Global Retinal Dystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinal Dystrophy Treatment Revenue in 2023
3.5 Retinal Dystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Retinal Dystrophy Treatment Product Solution and Service
3.7 Date of Enter into Retinal Dystrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Retinal Dystrophy Treatment Breakdown Data by Type
4.1 Global Retinal Dystrophy Treatment Historic Market Size by Type (2019-2024)
4.2 Global Retinal Dystrophy Treatment Forecasted Market Size by Type (2025-2030)
5 Retinal Dystrophy Treatment Breakdown Data by Application
5.1 Global Retinal Dystrophy Treatment Historic Market Size by Application (2019-2024)
5.2 Global Retinal Dystrophy Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Retinal Dystrophy Treatment Market Size (2019-2030)
6.2 North America Retinal Dystrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Retinal Dystrophy Treatment Market Size by Country (2019-2024)
6.4 North America Retinal Dystrophy Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Retinal Dystrophy Treatment Market Size (2019-2030)
7.2 Europe Retinal Dystrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Retinal Dystrophy Treatment Market Size by Country (2019-2024)
7.4 Europe Retinal Dystrophy Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Retinal Dystrophy Treatment Market Size (2019-2030)
8.2 Asia-Pacific Retinal Dystrophy Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Retinal Dystrophy Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Retinal Dystrophy Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Retinal Dystrophy Treatment Market Size (2019-2030)
9.2 Latin America Retinal Dystrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Retinal Dystrophy Treatment Market Size by Country (2019-2024)
9.4 Latin America Retinal Dystrophy Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Retinal Dystrophy Treatment Market Size (2019-2030)
10.2 Middle East & Africa Retinal Dystrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Retinal Dystrophy Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Retinal Dystrophy Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Spark Therapeutics (Roche)
11.1.1 Spark Therapeutics (Roche) Company Detail
11.1.2 Spark Therapeutics (Roche) Business Overview
11.1.3 Spark Therapeutics (Roche) Retinal Dystrophy Treatment Introduction
11.1.4 Spark Therapeutics (Roche) Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.1.5 Spark Therapeutics (Roche) Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Retinal Dystrophy Treatment Introduction
11.2.4 Novartis AG Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.2.5 Novartis AG Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Retinal Dystrophy Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Applied Genetic Technologies Corporation
11.4.1 Applied Genetic Technologies Corporation Company Detail
11.4.2 Applied Genetic Technologies Corporation Business Overview
11.4.3 Applied Genetic Technologies Corporation Retinal Dystrophy Treatment Introduction
11.4.4 Applied Genetic Technologies Corporation Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.4.5 Applied Genetic Technologies Corporation Recent Development
11.5 Oxford BioMedica
11.5.1 Oxford BioMedica Company Detail
11.5.2 Oxford BioMedica Business Overview
11.5.3 Oxford BioMedica Retinal Dystrophy Treatment Introduction
11.5.4 Oxford BioMedica Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.5.5 Oxford BioMedica Recent Development
11.6 Biogen
11.6.1 Biogen Company Detail
11.6.2 Biogen Business Overview
11.6.3 Biogen Retinal Dystrophy Treatment Introduction
11.6.4 Biogen Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.6.5 Biogen Recent Development
11.7 HORAMA S.A.
11.7.1 HORAMA S.A. Company Detail
11.7.2 HORAMA S.A. Business Overview
11.7.3 HORAMA S.A. Retinal Dystrophy Treatment Introduction
11.7.4 HORAMA S.A. Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.7.5 HORAMA S.A. Recent Development
11.8 MeiraGTx Limited
11.8.1 MeiraGTx Limited Company Detail
11.8.2 MeiraGTx Limited Business Overview
11.8.3 MeiraGTx Limited Retinal Dystrophy Treatment Introduction
11.8.4 MeiraGTx Limited Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.8.5 MeiraGTx Limited Recent Development
11.9 Novelion Therapeutics
11.9.1 Novelion Therapeutics Company Detail
11.9.2 Novelion Therapeutics Business Overview
11.9.3 Novelion Therapeutics Retinal Dystrophy Treatment Introduction
11.9.4 Novelion Therapeutics Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.9.5 Novelion Therapeutics Recent Development
11.10 IVERIC bio
11.10.1 IVERIC bio Company Detail
11.10.2 IVERIC bio Business Overview
11.10.3 IVERIC bio Retinal Dystrophy Treatment Introduction
11.10.4 IVERIC bio Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.10.5 IVERIC bio Recent Development
11.11 Reflection Biotechnologies
11.11.1 Reflection Biotechnologies Company Detail
11.11.2 Reflection Biotechnologies Business Overview
11.11.3 Reflection Biotechnologies Retinal Dystrophy Treatment Introduction
11.11.4 Reflection Biotechnologies Revenue in Retinal Dystrophy Treatment Business (2019-2024)
11.11.5 Reflection Biotechnologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Retinal Dystrophy Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Gene Therapy Treatment
Table 3. Key Players of Symptomatic Treatment
Table 4. Global Retinal Dystrophy Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Retinal Dystrophy Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Retinal Dystrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Retinal Dystrophy Treatment Market Share by Region (2019-2024)
Table 8. Global Retinal Dystrophy Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Retinal Dystrophy Treatment Market Share by Region (2025-2030)
Table 10. Retinal Dystrophy Treatment Market Trends
Table 11. Retinal Dystrophy Treatment Market Drivers
Table 12. Retinal Dystrophy Treatment Market Challenges
Table 13. Retinal Dystrophy Treatment Market Restraints
Table 14. Global Retinal Dystrophy Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Retinal Dystrophy Treatment Market Share by Players (2019-2024)
Table 16. Global Top Retinal Dystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retinal Dystrophy Treatment as of 2023)
Table 17. Ranking of Global Top Retinal Dystrophy Treatment Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Retinal Dystrophy Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Retinal Dystrophy Treatment Product Solution and Service
Table 21. Date of Enter into Retinal Dystrophy Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Retinal Dystrophy Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Retinal Dystrophy Treatment Revenue Market Share by Type (2019-2024)
Table 25. Global Retinal Dystrophy Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Retinal Dystrophy Treatment Revenue Market Share by Type (2025-2030)
Table 27. Global Retinal Dystrophy Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Retinal Dystrophy Treatment Revenue Market Share by Application (2019-2024)
Table 29. Global Retinal Dystrophy Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Retinal Dystrophy Treatment Revenue Market Share by Application (2025-2030)
Table 31. North America Retinal Dystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Retinal Dystrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Retinal Dystrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Retinal Dystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Retinal Dystrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Retinal Dystrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Retinal Dystrophy Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Retinal Dystrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Retinal Dystrophy Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Retinal Dystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Retinal Dystrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Retinal Dystrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Retinal Dystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Retinal Dystrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Retinal Dystrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. Spark Therapeutics (Roche) Company Detail
Table 47. Spark Therapeutics (Roche) Business Overview
Table 48. Spark Therapeutics (Roche) Retinal Dystrophy Treatment Product
Table 49. Spark Therapeutics (Roche) Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 50. Spark Therapeutics (Roche) Recent Development
Table 51. Novartis AG Company Detail
Table 52. Novartis AG Business Overview
Table 53. Novartis AG Retinal Dystrophy Treatment Product
Table 54. Novartis AG Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 55. Novartis AG Recent Development
Table 56. GlaxoSmithKline Company Detail
Table 57. GlaxoSmithKline Business Overview
Table 58. GlaxoSmithKline Retinal Dystrophy Treatment Product
Table 59. GlaxoSmithKline Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 60. GlaxoSmithKline Recent Development
Table 61. Applied Genetic Technologies Corporation Company Detail
Table 62. Applied Genetic Technologies Corporation Business Overview
Table 63. Applied Genetic Technologies Corporation Retinal Dystrophy Treatment Product
Table 64. Applied Genetic Technologies Corporation Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 65. Applied Genetic Technologies Corporation Recent Development
Table 66. Oxford BioMedica Company Detail
Table 67. Oxford BioMedica Business Overview
Table 68. Oxford BioMedica Retinal Dystrophy Treatment Product
Table 69. Oxford BioMedica Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 70. Oxford BioMedica Recent Development
Table 71. Biogen Company Detail
Table 72. Biogen Business Overview
Table 73. Biogen Retinal Dystrophy Treatment Product
Table 74. Biogen Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 75. Biogen Recent Development
Table 76. HORAMA S.A. Company Detail
Table 77. HORAMA S.A. Business Overview
Table 78. HORAMA S.A. Retinal Dystrophy Treatment Product
Table 79. HORAMA S.A. Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 80. HORAMA S.A. Recent Development
Table 81. MeiraGTx Limited Company Detail
Table 82. MeiraGTx Limited Business Overview
Table 83. MeiraGTx Limited Retinal Dystrophy Treatment Product
Table 84. MeiraGTx Limited Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 85. MeiraGTx Limited Recent Development
Table 86. Novelion Therapeutics Company Detail
Table 87. Novelion Therapeutics Business Overview
Table 88. Novelion Therapeutics Retinal Dystrophy Treatment Product
Table 89. Novelion Therapeutics Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 90. Novelion Therapeutics Recent Development
Table 91. IVERIC bio Company Detail
Table 92. IVERIC bio Business Overview
Table 93. IVERIC bio Retinal Dystrophy Treatment Product
Table 94. IVERIC bio Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 95. IVERIC bio Recent Development
Table 96. Reflection Biotechnologies Company Detail
Table 97. Reflection Biotechnologies Business Overview
Table 98. Reflection Biotechnologies Retinal Dystrophy Treatment Product
Table 99. Reflection Biotechnologies Revenue in Retinal Dystrophy Treatment Business (2019-2024) & (US$ Million)
Table 100. Reflection Biotechnologies Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Retinal Dystrophy Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Retinal Dystrophy Treatment Market Share by Type: 2023 VS 2030
Figure 3. Gene Therapy Treatment Features
Figure 4. Symptomatic Treatment Features
Figure 5. Global Retinal Dystrophy Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Retinal Dystrophy Treatment Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Retinal Dystrophy Treatment Report Years Considered
Figure 11. Global Retinal Dystrophy Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Retinal Dystrophy Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Retinal Dystrophy Treatment Market Share by Region: 2023 VS 2030
Figure 14. Global Retinal Dystrophy Treatment Market Share by Players in 2023
Figure 15. Global Top Retinal Dystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retinal Dystrophy Treatment as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Retinal Dystrophy Treatment Revenue in 2023
Figure 17. North America Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Retinal Dystrophy Treatment Market Share by Country (2019-2030)
Figure 19. United States Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Retinal Dystrophy Treatment Market Share by Country (2019-2030)
Figure 23. Germany Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Retinal Dystrophy Treatment Market Share by Region (2019-2030)
Figure 31. China Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Retinal Dystrophy Treatment Market Share by Country (2019-2030)
Figure 39. Mexico Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Retinal Dystrophy Treatment Market Share by Country (2019-2030)
Figure 43. Turkey Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Retinal Dystrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Spark Therapeutics (Roche) Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 46. Novartis AG Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 47. GlaxoSmithKline Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 48. Applied Genetic Technologies Corporation Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 49. Oxford BioMedica Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 50. Biogen Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 51. HORAMA S.A. Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 52. MeiraGTx Limited Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 53. Novelion Therapeutics Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 54. IVERIC bio Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 55. Reflection Biotechnologies Revenue Growth Rate in Retinal Dystrophy Treatment Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
